- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Inhibikase Therapeutics beruft Scott Wasserman in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| Di | Inhibikase appoints Scott Wasserman to board of directors | 1 | Investing.com | ||
| 13.10. | Chardan initiates Inhibikase Therapeutics stock with neutral rating | 2 | Investing.com | ||
| 13.10. | Chardan startet Coverage für Inhibikase Therapeutics mit neutralem Rating | - | Investing.com Deutsch | ||
| 02.10. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 08.09. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | Biotech Stocks At 52-Week Highs - Vogenx, Pharvaris, Solventum, Inhibikase Therapeutics, HeartFlow | 1.201 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 24, 2026, driven by positive results from clinical trials or an upcoming conference participation. Vogenx... ► Artikel lesen | |
| 11.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 in-line | 1 | Seeking Alpha | ||
| 11.08. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity | 271 | GlobeNewswire (Europe) | WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily... ► Artikel lesen | |
| 23.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.07. | Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH | 403 | GlobeNewswire (Europe) | WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 15.07. | Biotech Stocks Hit 52-Week Highs - The Oncology Institute, Inhibikase Therapeutics, Alto Neuroscience, Elevance Health, Privia Health | 874 | AFX News | WASHINGTON (dpa-AFX) - These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business... ► Artikel lesen | |
| 14.07. | Inhibikase sells $50M of common stock to RA Capital | 1 | Seeking Alpha | ||
| 14.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility | 399 | GlobeNewswire (Europe) | WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 02.07. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 253,00 | -0,16 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 39,990 | -1,54 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| EYEPOINT | 0,388 | +1,04 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,834 | 0,00 % | Aurora Cannabis: Organigram funkt Curaleaf dazwischen | ||
| QUANTUM BIOPHARMA | 2,286 | +11,30 % | Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company focused on developing innovative therapies and technologies... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 34,170 | +0,21 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| AMARIN | 9,950 | -3,40 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,600 | +2,21 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| JAZZ PHARMACEUTICALS | 189,15 | +0,26 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 | Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,600 | -2,30 % | EILMELDUNG: Könnte die Aktie von SELLAS Life Sciences Group nach 15,0 % Plus jetzt komplett durchstarten? - Das dürfen Sie nicht verpassen! | ||
| MADRIGAL PHARMACEUTICALS | 421,90 | +3,46 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,854 | +1,82 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 60,63 | +0,53 % | BridgeBio Pharma, Inc.: BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET | ||
| OPUS GENETICS | 3,640 | -1,09 % | Opus Genetics receives FDA clearance for RDH12-LCA gene therapy | ||
| SAVARA | 4,034 | -2,87 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.